reason report
solid result busi show rebound pt
core busi seem show good rebound good
gross margin growth appar solid retent expect
seemingli highli effect clinic program also like esrx
push much earn tax benefit
adjust ep clearli balanc need busi
expect sharehold view op re-
invest back platform may long-term benefit
busi howev would much rather see
focu sharehold return clinic program seem
work well safeguardrx product gain traction
wbad jv effect improv gener procur
rate synergi like realiz specialti spend
complex product start flow wbad
optimist outlook evicor given improv
fundament increas estim pt
compani ms valu program launch alreadi
live make highli effect launch manag said
major compani safeguardrx program enrol
live still room grow could
doubl next year compani continu see stream
interest opportun build addit new program
record year program up-sel esrx client retent rate
trend high management said retent track toward base
call sound like major larg renew
start complet impress drug trend
includ specialti client neg
trend view highlight firm abil drive clinic
efficaci accord manag implement
smooth believ client satisfact score esrx
high
esrx continu drive margin call manag highlight
realiz gener purchas synergi wbad
deal expect realiz specialti buy synergi
complex product move wbad jv time believ
real benefit buy consortium respect specialti
bio-similar esrx believ bio-similar meaning arriv
 mani held court bio-similar
neulasta expect late big one like humira
could late market migrat bio-similar
take time esrx continu gain traction specialti gener
safeguardrx program
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu billion ep adjust non-cash non-recur item
pleas refer page import disclosur price chart analyst certif
sell season start call esrx highlight
earli success sell season indic
renew complet manag also note propos
cvs/aet mp merger signific impact result
time still earli tell market react larger win
esrx receiv prospect year ago
sell season start manag said amount
renew normal normal compar prior year
also intrigu svp chief medic offic dr miller comment
evicor asset indic platform
abl aggress manag integr medic
pharmaci spend client still earli cross-sel
evicor book busi manag highlight
evicor asset robust pipelin
guidanc reiter full year guidanc reiter
compani continu expect adj ep rang
attribut tax reform pleas
esrx take consider need sharehold
compar leerink/consensu repres y/i growth
midpoint quarterli cadenc earn expect
similar higher ramp compani see higher
util program increas gener throughout year also
esrx plan spend enterpris valu initi plan
realiz save within year one-tim employe
bonu pool tax reform save includ guidanc
updat estim pt increas
ep respect slightli better gross
margin cost control optimist underli
fundament busi sound clinic program
highli effect retent rate improv evicor asset
may good respons effect sold pbm
consult commun like esrx drive margin
wbad relationship increas pt improv
sentiment fundament howev pbm market remain
competit believ esrx price aggress
cvs/aet combin would formid competitor result
maintain mp rate
express script one largest pharmaci benefit manag pbm countri term
adjust script market believ pbm industri whole
benefit continu launch gener drug ii increas mail penetr iii
wave specialti drug insur compani self-insur employ group need
manag iv bio-similar estim gener drug dispens mail-ord
facil profit brand drug dispens non-own retail store
accord feder trade commiss ftc acquisit nextrx close
decemb esrx enter agreement wellpoint
perform pbm function member howev esrx face loss
largest client though larg built investor expect compani acquir
medco health solut april solidifi esrx posit largest pbm esrx
strong cash flow gener success integr acquisit onto singl
platform specialti drug come market believ employ group look
way control cost especi face recessionari pressur mani
theme benefit esrx past sever year mail penetr rate start
stagnat gener launch slow loss creat signific earn
challeng result rate share esrx market perform
esrx share current trade adjust ep estim
histor averag next month expect share
trade ep repres discount
compani histor averag exclud ep would
account transit client stock would trade antm-
adjust ep pt would antm-adjust ep
encourag specialti growth comment around re-invest back
platform believ servic level improv although believ esrx
price aggress retain custom believ esrx better posit
head given servic improv see opportun win increment
share although stagnat mail penetr rate slowdown gener launch repres
threat key pillar esrx busi model view claim growth stagnat
believ esrx longer compel risk/reward profil activ highli
competit pbm marketplac next two year rate esrx share market perform
complianc extens healthcar law regul place govern pbm
behavior state feder level mani law regul pertain fraud
abus privaci consum protect plan design restrict drug price medicar
medicaid reimburs drug import insur regul
signific custom concentr esrx depend relationship retail
pharmaci dispens prescript member compani lose materi amount
contract abil dispens medic member could impair potenti
result loss busi given esrx largest pbm term
adjust prescript think unlik retail chain would termin contract
compani loss contract creat signific earn headwind
pbm market competit pbm industri highli competit account come
renew put bid variou competitor includ like bid
aggress offer servic appear modestli differ esrx contract
typic last three year retent rate usual high level
competit allow client demand price reduct and/or larger share rebat
healthcar reform pbm risk legal process surround healthcar reform
believ transpar languag materi impact
pbm could prove risk busi client may seek higher share rebat
wholesal may tri negoti favor term
good sold
revenu
revenu
revenu
